Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II/III trial of UB-612 vaccine

Next Previous
X
Search
Trial Profile

Phase II/III trial of UB-612 vaccine

Status: Planning
Phase of Trial: Phase II/III

Latest Information Update: 17 Sep 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs UB 612 (Primary)
  • Indications COVID 2019 infections
  • Focus Therapeutic Use
  • Sponsors United Biomedical

    • Most Recent Events

    • 17 Sep 2020 New trial record
    • 23 Aug 2020 According to United Biomedical, Inc. (UBI) media release, the company has proposed subsidies to the US Department of Defense and the Coalition for Epidemic Preparedness Innovations (CEPI) for conducting human clinical trials in the United States. The application is expected to start this trial in USA by the end of this year based on the results of Taiwan's Phase I dose-escalation trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top